Only 3 in 20 new drugs approved in Germany in 2011 were an improvement, report saysBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g2657 (Published 08 April 2014) Cite this as: BMJ 2014;348:g2657
- Ned Stafford
Nearly 85% of new drugs in Germany that were approved in 2011 for outpatients covered by public health insurance showed little or no added benefit compared with drugs already on the market, says a new study commissioned by Techniker Krankenkasse, Germany’s largest public health insurer.
However, the authors of the annual study, Innovation Report 2014,1 noted that “drug innovation” figures for 2011 were an improvement on 2010 and that they expected the improvement to continue in the coming years, mainly because of a new German drug law.
Of the 20 new drugs approved in 2011 that …